... If NSAIDs do not adequately control inflammation, rheumatologists may prescribe biologic medications, such as adalimumab (Humira), infliximab-dyyb (Inflectra), or golimumab (Simponi). ...
... If NSAIDs do not adequately control inflammation, rheumatologists may prescribe biologic medications, such as adalimumab (Humira), infliximab-dyyb (Inflectra), or golimumab (Simponi). ...
... Disease-modifying antirheumatic drugs, such as methotrexate, adalimumab (Humira), infliximab (Inflectra), and golimumab (Simponi), can help delay fusing of the vertebral bodies of the spine. These treatments may prevent or delay the progression of axial spondyloarthritis from evolving to radiographic axial spondyloarthritis. ...
... Disease-modifying antirheumatic drugs, such as methotrexate, adalimumab (Humira), infliximab (Inflectra), and golimumab (Simponi), can help delay fusing of the vertebral bodies of the spine. These treatments may prevent or delay the progression of axial spondyloarthritis from evolving to radiographic axial spondyloarthritis. ...
... The mainstay treatments for spondyloarthritis are disease-modifying antirheumatic drugs (DMARDs), such as methotrexate and biologic tumor necrosis factor (TNF) inhibitors adalimumab (Humira), infliximab-dyyb (Inflectra), and golimumab (Simponi).Starting treatment early can delay or even prevent irreversible spine curvature, limited mobility, and disability ...
... The mainstay treatments for spondyloarthritis are disease-modifying antirheumatic drugs (DMARDs), such as methotrexate and biologic tumor necrosis factor (TNF) inhibitors adalimumab (Humira), infliximab-dyyb (Inflectra), and golimumab (Simponi).Starting treatment early can delay or even prevent irreversible spine curvature, limited mobility, and disability ...